drugset / Trial / NCT03719664
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.
Timeline
- Start
- 2018-12-17
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albuvirtide | Other / unclassified | 0.16 g | Intravenous |
| Subject | Albuvirtide | Other / unclassified | 0.32 g | Intravenous |
| Subject | LAFUVITUG | Monoclonal antibody | 0.8 g | Intravenous |
| Subject | LAFUVITUG | Monoclonal antibody | 2 g | Intravenous |